Weight loss
A once-weekly GLP-1 injection (Trulicity), FDA-approved for type 2 diabetes — it lowers blood sugar, trims a few kilograms, and protects the heart.
Start here
Dulaglutide, sold as Trulicity, is an FDA-approved once-weekly injection for type 2 diabetes that mimics GLP-1, a gut hormone that helps control blood sugar and appetite. In clinical trials it lowered HbA1c (a measure of average blood sugar) by 1.5-1.9% 45, produced weight loss of about 3-4.6 kg 1, and reduced major cardiovascular events 6. It comes in a pre-filled pen and is also approved for children aged 10 and up with type 2 diabetes 26.
Dulaglutide (Trulicity) is a once-weekly GLP-1 (a gut hormone that tells your brain you're full) hormone mimic that helps your pancreas release insulin when blood sugar is high, slows stomach emptying to reduce appetite, and activates your brain's appetite control center—delivering powerful blood sugar control and steady weight loss.
Dulaglutide is a 63-kDa fusion protein (two proteins joined into one large molecule). It combines a modified human GLP-1(7-37) (a gut hormone that controls blood sugar; changes: Ala8Gly, Gly22Glu, Arg36Gly) with the Fc part of a modified human IgG4 antibody (a section that helps proteins last in the blood), joined by a 13-amino acid linker (GGGGGGGSGGGGSG). The result is a two-part (homodimeric) structure. This design lets the body recycle it through FcRn (a recycling receptor), giving a long half-life (~5 days) while it still strongly activates the GLP-1 receptor. Dulaglutide switches on GLP-1 receptors on pancreatic beta cells (insulin-making cells) to release insulin only when blood sugar is high. It lowers glucagon (a hormone that raises blood sugar) from alpha cells when blood sugar is high, slows stomach emptying through signals along the vagus nerve, and switches on GLP-1 receptors in the hypothalamus (the brain's appetite center) to make you feel full and eat less.
Evidence check
Well studied in people
This has been through large human trials — the strongest kind of evidence. Scientists have tested it on many people and measured what actually happened.
Every numbered marker on this page links to one of the 6 sources at the bottom.
Metabolism (how the body uses energy)
Delivers strong blood sugar control, with HbA1c (3-month average blood sugar) down 1.5–1.9% across the 11-trial AWARD program, better than or about as good as most diabetes comparators. Higher doses (3.0 and 4.5 mg) work even better. It also has proven heart-event reduction.
Weight Management
Promotes weight loss of 3.0–4.6 kg that grows with the dose, along with better heart-risk numbers: cholesterol down by up to 6.0%, VLDL (a type of "bad" blood fat) down by up to 19.4%, triglycerides (another blood fat) down by up to 21.5%, and systolic blood pressure (the top number) down by up to 5.6 mmHg
Healing & Recovery
REWIND trial demonstrated reduction in major adverse cardiovascular events, earning an FDA-approved cardiovascular outcomes indication — providing long-term cardioprotection in type 2 diabetes patients with or without established CVD
The most-asked question
Dulaglutide is dose-escalated: the studies start everyone low and step the dose up on a schedule, so the right amount depends on the week you're on. The research-reported maintenance range is 1.5 mg, once weekly.
4 weeks before increasing
0.75 mg
FDA-approved starting dose for type 2 diabetes. Injected under the skin of the abdomen, thigh, or upper arm on the same day each week 4.
Ongoing
1.5 mg
Common maintenance dose. The dose can be raised from 0.75 mg after at least 4 weeks if more blood-sugar control is needed 14.
Ongoing
3.0–4.5 mg
FDA-approved higher doses. In the AWARD-11 trial, stepping up to 3.0 mg then 4.5 mg gave added blood-sugar and weight benefits; 4.5 mg is the maximum dose 1.
The ceiling: 4.5 (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Dulaglutide:
Add the recommended volume of bacteriostatic water to the Dulaglutide vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Dulaglutide is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Dulaglutide's recorded schedule.
Injection sites & technique
Subcutaneous (under the skin) injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Timing
Administer Dulaglutide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
Dulaglutide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
Dulaglutide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Occurs in 13.4–16.4% of patients depending on dose. Generally mild to moderate, most pronounced during the first weeks and dose escalation. 6 Lower incidence than many other GLP-1 (a gut hormone that tells your brain you're full) RAs.
What to do Gradual dose titration (stepping the dose up gradually) over 4-week intervals. Eat smaller, more frequent meals. Most patients develop tolerance within 4–6 weeks. Nausea rates with dulaglutide are among the lowest in the GLP-1 (a gut hormone that tells your brain you're full) RA class.
Common stomach and gut effects of the drug acting on GLP-1 (a gut hormone that tells your brain you're full) receptors (the docking points it acts on). Usually mild to moderate and clear up on their own 6.
What to do Stay hydrated. Dietary adjustments as needed. Generally improves with continued therapy.
Reported in 5.6–9.3% of patients, dose-dependent. More common during dose escalation periods.
What to do Ensure gradual dose titration (stepping the dose up gradually). Temporarily hold at current dose if persistent. Consider anti-emetics short-term if needed.
Lower appetite is an expected drug effect, caused by the drug acting on GLP-1 (a gut hormone that tells your brain you're full) receptors (docking points) in the brain. It adds to the weight loss benefit of dulaglutide 6.
What to do Generally considered a therapeutic benefit. Ensure adequate nutrition is maintained despite reduced appetite.
Worth knowing about, but most people never see these.
Mild injection site reactions and transient fatigue may occur, particularly during the first few weeks of therapy. The autoinjector pen minimizes injection-related issues.
What to do Rotate injection sites. Fatigue usually fades as your body adjusts to the drug's effect on GLP-1 (a gut hormone that tells your brain you're full) receptors (the docking points it acts on).
Rare, but if any of these happen, stop and contact a medical professional.
Rare but reported in clinical trials. Risk factors include gallstones, very high blood fats (hypertriglyceridemia), and a past history of pancreatitis. 6 Shows up as severe, lasting belly pain.
What to do Discontinue dulaglutide immediately if pancreatitis is suspected. Do not restart after confirmed pancreatitis. Monitor amylase/lipase if symptoms suggest pancreatic inflammation.
Cholelithiasis (0.5%) and cholecystitis (0.3%) reported at slightly higher rates than placebo, 6 likely related to weight loss effects on bile composition.
What to do Monitor for symptoms of gallbladder disease. Imaging evaluation if right upper quadrant pain develops. May require surgical intervention in severe cases.
Week by week
Is it right for you?
Dulaglutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
May be used together under medical guidance.
May be used together under medical guidance.
May be used together under medical guidance.
Generally safe to take alongside Dulaglutide. Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Dulaglutide is particularly well-suited for individuals focused on type 2 diabetes patients seeking convenient once-weekly dosing with strong glycemic control (keeping blood sugar steady). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Dulaglutide is particularly well-suited for individuals focused on patients with established cardiovascular disease or multiple cv risk factors seeking rewind-proven cardioprotection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Dulaglutide is particularly well-suited for overweight or obese people with type 2 diabetes who need both weight loss and a lower HbA1c (3-month average blood sugar). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Dulaglutide is particularly well-suited for individuals focused on pediatric patients aged 10–17 with type 2 diabetes (approved indication). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Dulaglutide is an FDA-approved GLP-1 receptor agonist (it switches on the GLP-1 (a gut hormone that tells your brain you're full) docking points). It carries a black box warning (the FDA's strongest warning) for thyroid C-cell tumor risk, based on rodent data showing more medullary thyroid cancer (MTC, a rare thyroid cancer) in rats. It must not be used by anyone with a personal or family history of MTC 6 or multiple endocrine neoplasia type 2 (an inherited condition that causes tumors in hormone glands). Nausea occurs in 20-40% of patients, rises with dose, and is worst at the start. Other stomach side effects (vomiting, diarrhea) are common. Pancreatitis (inflamed pancreas) has been reported in 0.1-0.2% of patients: stop immediately if severe belly pain develops. Rapid weight loss can trigger gallstones. Dehydration risk is significant, especially with SGLT2 inhibitors (diabetes pills that make you pass sugar in your urine). Injection site reactions are mild but frequent.
Dulaglutide was studied through Phase 3 randomized controlled trials for type 2 diabetes (AWARD program) 14 with thousands of patients, providing robust safety data. The FDA black box warning reflects preclinical (animal or lab studies, not human trials) evidence in animal models combined with post-market surveillance over 10+ years. Comparative efficacy and safety trials with other GLP-1 (a gut hormone that tells your brain you're full) agonists (semaglutide, liraglutide) provide substantial evidence base for risk-benefit analysis.
Keeping it good
Store Dulaglutide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Dulaglutide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2021
Higher dulaglutide doses (3.0-4.5 mg) lowered HbA1c (a blood test of average blood sugar) and weight more than the standard 1.5 mg dose in 1,842 patients with type 2 diabetes.
Frias JP, Bonora E, Nevarez Ruiz L, et al.
2022
Clinical evidence (2022) supports the therapeutic use of dulaglutide in medical treatment protocols.
Arslanian SA, Hannon T, Zeitler P, et al.
2022
Research (2022) on dulaglutide contributes important scientific knowledge about its biological and pharmacological properties.
Cox DA, Wang H, Nicolay C, et al.
2017
Clinical evidence (2017) supports the therapeutic use of dulaglutide in medical treatment protocols.
Scheen AJ
2016
Clinical evidence (2016) supports the therapeutic use of dulaglutide in medical treatment protocols.
Scheen AJ
2023
Label effective 2023-08-05 (retrieved via openFDA brand_name.exact TRULICITY, brand/generic verified): contraindicated (must not be used) with a personal or family history of MTC (medullary thyroid carcinoma, a thyroid cancer) or MEN 2 (multiple endocrine neoplasia type 2, an inherited cancer syndrome) and with serious hypersensitivity (allergy) to dulaglutide; not for treatment of type 1 diabetes; not recommended in severe gastrointestinal disease including severe gastroparesis (a stomach that empties very slowly); has not been studied in patients with a history of pancreatitis (an inflamed pancreas); monitor patients with a history of diabetic retinopathy (diabetes-related eye damage).
Eli Lilly and Company
If this isn't the right fit
Your questions
Dulaglutide is unique in its molecular design — it is a GLP-1 (a gut hormone that tells your brain you're full) analog (a modified version of a natural molecule) fused to a modified IgG4 Fc fragment, creating a large (~63 kDa) fusion protein that resists both DPP-4 degradation and renal clearance. This provides a true 5-day half-life (how long it stays active in your body) enabling once-weekly dosing. It also comes in a ready-to-use pre-filled autoinjector pen that requires no reconstitution, making it one of the simplest GLP-1 RA injection methods available.
Dulaglutide comes in four strengths: 0.75 mg (starting dose), 1.5 mg (standard dose), 3.0 mg, and 4.5 mg (higher doses approved in 2020 for a stronger effect). AWARD-11 showed that 4.5 mg lowers HbA1c (your 3-month average blood sugar) more (-1.77% vs -1.54%) and gives more weight loss (-4.6 kg vs -3.0 kg) than 1.5 mg.
Yes. Dulaglutide (Trulicity) is FDA-approved for type 2 diabetes in young people aged 10 to under 18, based on the AWARD-PEDS trial. In that trial, 51% of those taking dulaglutide reached an HbA1c (3-month average blood sugar) below 7.0%, compared with 14% on placebo. That makes it an effective option for type 2 diabetes in young people.
Yes. The REWIND trial showed that dulaglutide lowers the rate of major heart events (such as heart attack and stroke) in adults with type 2 diabetes. This led to an FDA-approved heart-protection use in June 2022. Higher doses also improve cholesterol, triglycerides (a type of blood fat), and blood pressure, with bigger improvements at higher doses.
Yes. No dose change is needed for any level of kidney or liver impairment. The AWARD-7 trial tested dulaglutide in people with chronic kidney disease. It controlled blood sugar about as well as insulin glargine (a long-acting insulin) and had a good kidney safety record.
Semaglutide generally produces greater weight loss than dulaglutide — up to 15% of body weight at the highest doses (Wegovy 2.4 mg) versus 3–5% with dulaglutide. However, dulaglutide has its own FDA-approved cardiovascular outcomes indication, a convenient autoinjector pen, and the broadest range of dose options (0.75–4.5 mg weekly) among GLP-1 (a gut hormone that tells your brain you're full) RAs, allowing flexible dose optimization.
6 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Dulaglutide research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Talk to a clinician before taking anything.
PeptideGeek